Insider Trading Alert - BIIB, CTBI And ENSG Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 16, 2015, 79 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $442.00 to $2,999,379.00.

Highlighted Stocks Traded by Insiders:

Biogen (BIIB) - FREE Research Report

Posner Brian S, who is Director at Biogen, sold 400 shares at $386.64 on June 16, 2015. Following this transaction, the Director owned 5,745 shares meaning that the stake was reduced by 6.51% with the 400-share transaction.

The shares most recently traded at $390.78, up $4.14, or 1.06% since the insider transaction. Historical insider transactions for Biogen go as follows:

  • 4-Week # shares sold: 1,362
  • 12-Week # shares sold: 11,460
  • 24-Week # shares sold: 23,551

The average volume for Biogen has been 1.8 million shares per day over the past 30 days. Biogen has a market cap of $91.3 billion and is part of the health care sector and drugs industry. Shares are up 14.38% year-to-date as of the close of trading on Tuesday.

Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. The company has a P/E ratio of 28.1. Currently, there are 10 analysts who rate Biogen a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BIIB - FREE

TheStreet Quant Ratings rates Biogen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Biogen Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

European Pharma Companies Slip on MS Pricing Probe

Biogen Stock Climbs After Goldman Adds to its 'Conviction Buy' List

Pfizer's Poor Earnings Feed the Allergan Tie-Up Fire